| Name | Genflow Biosciences |
|---|---|
| Epic | GENF |
| Isin | GB00BP2C3V08 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1.73p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £6.03 | Debt ratio | n/a |
| Shares in issue | 349.71 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -56.41 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.46 | 52-week high / low | 1.38p / 3.30p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Genflow Biosciences |
|---|---|
| Address | Suite 1, 15 Ingestre Place, London, United Kingdom, W1F 0DU |
| Telephone | +44 (0)208 142 5409 |
| Website | http://genflowbio.com/ |
| Director | Position |
|---|---|
| Dr Eric Leire | CEO |
| Dr Yassine Bendiabdallah | Non-Executive Chairman |
| Ms Tamara Joseph | Independent Non-Executive Director |
| Dr Peter King-Lewis | Independent Non-Executive Director |
| Dr Guy-Charles Fanneau de la Horie | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 |
|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | n/a | n/a |
| Investments and other non-current assets | n/a | n/a |
| Total non-current assets | n/a | n/a |
| Inventory / work in progress | n/a | n/a |
| Trade and other receivables | 0.26 | 0.05 |
| Cash and equivalents | 2.36 | 0.22 |
| Other current assets and asset held for resale | n/a | n/a |
| Total of all assets | 2.62 | 0.28 |
| Liabilities £ (m) | 2022 | 2021 |
|---|---|---|
| Short term liabilities | 0.25 | 0.22 |
| Long term liabilities | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a |
| Total of all liabilities | 0.25 | 0.22 |
| Net assets £ (m) | 2022 | 2021 |
|---|---|---|
| Net assets | 2.37 | 0.06 |
| Equity £ (m) | 2022 | 2021 |
|---|---|---|
| Share capital | 0.09 | 0.07 |
| Minority interests | n/a | n/a |
| Retained earnings | -2.14 | -0.81 |
| Share premium account | 4.19 | 0.63 |
| Total equity | 2.37 | 0.06 |
| Income £ (m) | 2022 | 2021 |
|---|---|---|
| Turnover | n/a | n/a |
| Operating profit | -1.33 | -0.99 |
| Pre-tax profit | -1.34 | -0.99 |